We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 605

EU Court of Justice Advocate General issues ruling on Stem Cell patentability

  • Shook Hardy & Bacon LLP
  • -
  • European Union, United Kingdom
  • -
  • August 7 2014

In a non-binding ruling, Advocate General Cruz Villalón of the EU Court of Justice has determined that unfertilized human ova whose division

Ninth Circuit okays pharma waste disposal ordinance

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 30 2014

The Ninth Circuit Court of Appeals has upheld the validity of an Alameda County ordinance that requires prescription drug producers that sell brand

Report highlights growth in oncology R&D among midcap biotechs

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 21 2013

Business intelligence company GlobalData has released a report on mid-cap biotech companies and concludes that their research and development (R&D

Duke U. Economics Prof discusses prospects for biosimilars in U.S.

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 12 2014

Duke University Professor Emeritus and Director of the Program in Pharmaceutical Health Economics Henry Grabowski has co-authored a paper on

Nagoya genetic resources protocol enters into force

  • Shook Hardy & Bacon LLP
  • -
  • Global, USA
  • -
  • October 30 2014

The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilization entered into force

News Bytes - June 6, 2013

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 6 2013

The U.S. Patent and Trademark Office creates the After Final Consideration Pilot Program 2.0 which modifies and extends a program designed to

Indian Supreme Court rules Novartis cancer drug change not patentable

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • April 4 2013

The Supreme Court of India has rejected the patent application filed by Novartis AG for a beta crystalline form of its cancer drug Gleevec, also

FDA prosecutes drug importer on counterfeit drug charges

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 1 2013

The U.S. Food and Drug Administration (FDA) recently announced that a Montana resident who served as a consultant to a company that imported

FDA brings successful enforcement actions against dietary supplement makers

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 1 2012

The U.S. Food and Drug Administration (FDA) has obtained a permanent injunction against Truman Berst who sells, as Alternative Health & Herbs Remedies, herbs and dietary supplements with disease-treatment claims

India to ban PET packaging for certain pharmaceuticals

  • Shook Hardy & Bacon LLP
  • -
  • India, USA
  • -
  • January 9 2014

Citing increasing concerns about potential adverse health effects, the Indian Health Ministry is reportedly considering prohibiting the use of